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Abstract
Axillary clearance provides important prognostic information but is associated with significant
morbidity. Sentinel node biopsy can provide staging .141 patients with node negative early breast
cancers-tumour size less than 1.5 cm measured clinically or by imaging had guided axillary sampling
(sentinel lymph node biopsy in combination with axillary sampling). Four node axillary sampling
improved the detection rate of axillary node metastases by 13.6% as compared to blue dye sentinel
node biopsy alone. Positive sampled nodes strongly indicated the likelihood of further metastatic
being revealed by axillary dissection (67%). Negative sampled nodes in combination with a positive
sentinel node biopsy were associated with a much lower rate of further nodal involvement in the
axillary clearance (8%).
Introduction
For patients with early breast cancer axillary lymph node
status is the single most important prognostic indicator
enabling decisions regarding adjuvant systemic treatment
[1,2]. Axillary clearance remains the most accurate
method of staging the axilla but the procedure is associ-
ated with significant morbidity [3-5].
The likelihood of lymph node metastases is a function of
tumour size, particularly for small cancers, the incidence
of which is increasing [6,7]. Elective axillary dissection
may be over-treatment for a high proportion of such cases.
Many studies have indicated that the sentinel node biopsy
(SNB) concept is applicable to patients with early breast
cancer [8] and Veronesi has suggested that the procedure
might be limited to tumours of 15 mm or less [9]. SNB is
being validated in randomised trials NSABP B32, ACOS-
OG and the ALMANAC study but it will be some years
before long-term results are available. These studies, how-
ever, include larger tumours and will require subset anal-
ysis to study the outcome for small tumours.
The SNB concept suggests removal of the single first node
draining the tumour lymph however many of the reports
have described excision of multiple lymph nodes [10-15].
Previous reports of 4 or 5 node axillary sampling have sug-
gested accuracy rates equivalent to SNB [13-15]. We have
sought to determine whether the planned removal of at
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least 4 axillary nodes increases the accuracy of axillary
staging above that of the removal of the sentinel node.
Materials and methods
Between January 1998 and December 2002, patients with
clinically node negative early breast cancers-tumour size
less than or equal to 15 mm (measured clinically or by
imaging) had guided axillary sampling (sentinel lymph
node biopsy followed by excision of further nodes to
ensure a minimum of four nodes had been removed).
Sentinel node biopsy technique
Sentinel node biopsy (SNB) was performed using the dye
technique only without the adjunct of radioisotope label-
ling and gamma probe. Five mls of patent blue dye was
infiltrated peritumorally or subcutaneously in palpable
cancers, around the guide wire tip in impalpable cancers
or into the cavity wall when performed as a secondary
procedure to initial tumour excision.
After 5 minutes, a small low axillary incision was used to
identify blue stained afferent lymphatics which were
traced to the first blue stained sentinel node or nodes. All
blue stained nodes were excised and sent in a separate pot
labelled sentinel nodes.
Axillary sampling technique
Following excision of the sentinel node(s), at least three
further palpable lymph nodes were excised, labelled as
axillary node sample (ANS) and sent separately for histo-
logical analysis.
Wide local excision of the breast tumour was performed in
the usual way, only after sentinel node biopsy and axillary
node sampling were completed. All lymph nodes were
examined histopathologically using H&E staining. A level
three completion axillary clearance (ANC) was subse-
quently performed for patients who had metastatic
tumour cells identified histologically in the sentinel node
or sampled axillary lymph nodes. Further treatment
included radiotherapy and adjuvant hormonal or chemo-
therapy as per local guidelines.
Results
142 operations were performed on 141 patients whose
ages ranged from 30 to 85 years of age (mean = 60). 83
patients with 84 cancers were referred from the National
Health Service Breast Screening Programme (NHSBSP).
Of these 5 lesions were palpable. Of the remaining 58
patients not from screening, 18 had impalpable cancers.
The 45 palpable cancers ranged in size from 5 to 15 mm
(mean 11 mm). Of 98 lesions measurable on mammog-
raphy, size ranged from 4 to 15 mm (mean 10 mm). The
108 cancers measured on ultrasound ranged from 2.6 to
15 mm (mean 8.5 mm).
Ninety-nine lesions required localisation to guide their
breast excision. The localisation was performed with
mammographic guidance in 33 cases and with ultrasound
guidance in 66. In 27 cases, axillary surgery was performed
at a separate operation to the breast resection.
One hundred and twenty eight cases of the 142 (90.14%)
had successful identification of a sentinel node (Figure 1).
The median sentinel node biopsy count was 1(mean =
1.47), median axillary node count was 4 (mean = 4.65)
and the median total node count for SNB and ANS was 6
(mean = 6.13).
The finding of a negative sentinel node was correctly pre-
dictive of no further nodal metastasis in 106 of 109 cases
(97%). In the three cases with a negative sentinel node but
positive sampled nodes, the axillary clearance found fur-
ther positive nodes in 2 of 3 cases. When the sentinel node
was positive (19 of 128 cases, 14.8%), the axillary node
sampling was also positive in 32% (6 of 19 cases).
The finding of negative nodes in the axillary sampling
after a positive sentinel node indicated that axillary clear-
ance was unlikely to reveal further positive nodes (1 of 12
cases; 8%). The combination, however, of a positive sen-
tinel node and positive axillary sampling, indicated that
axillary clearance was highly likely to be positive (4 of 6
cases; 67%).
In 14 patients a sentinel node could not be identified
(9.9%). In these patients, 68 nodes were removed (3–5
nodes per patient). In two patients, a total of only 3 nodes
were found on histological examination. All other
patients had 4 or more nodes excised. Only one of these
Incidence of nodal disease for patients with small breast can- cers Figure 1
Incidence of nodal disease for patients with small 
breast cancers. SNB – sentinel node biopsy ANS – axillary 
node sample ANC – axillary node clearance * One patient 
with positive SNB but negative ANS received reduced dose 
radiotherapy to the axilla rather than undergoing ANC.International Seminars in Surgical Oncology 2005, 2:27 http://www.issoonline.com/content/2/1/27
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13 patients had axillary metastasis identified and this was
in a single lymph node – subsequent axillary clearance
failed to reveal any further malignant nodes in this
patient.
Twenty five of one hundred and forty two tumours (18%)
tumours were found to be greater than 15 mm in diameter
on final histology (Table 1). Of these, 13 cases had posi-
tive nodes identified (13/25, 52%) with 11 of them hav-
ing a positive sentinel node (11/13, 85%). Eight of 117
tumours with histological size less than or equal to 15
mm were found to be SNB positive with subsequent axil-
lary sampling identifying 2 ANS positive cases (2/8, 25%)
(Table 1).
Sixty-eight tumours measured less than 11 mm. Of these,
64 were SNB negative and 4 were SNB positive (3 ANS
negative, 1 ANS positive) (Table 1).
Of 141 tumours where the ER status was known, 13 were
ER negative and of these 3 (23%) were node positive at
surgery, whilst 128 ER positive and of these15 (12%)
node positive at operation. The single ER unknown
patient was node positive (Table 1).
Discussion
Axillary node dissection has previously been regarded as
an essential component of the management of patients
with early breast cancer [16]. Whilst neither reaches the
accuracy of axillary clearance, the low error rate of sentinel
node biopsy and unguided axillary sampling has lead to
proponents arguing the appropriateness of both tech-
niques [10,12,13]. If it is accepted that the necessity of full
axillary clearance is now an outmoded concept inappro-
priate for many patients with small breast cancers, then
several issues still require clarification to ensure the maxi-
mum efficiency of limited axillary surgery. Whilst there
are limitations of our study, we have sought to explore
some of these aspects.
In this study, using blue dye was successful in revealing a
sentinel node in 90% of cases. Finding a negative sentinel
node was highly predictive of further nodes in the axilla
being clear of cancer. However the simple extension of
removing four nodes in total ensured that the 3% of cases
with positive nodes but a negative SNB were correctly
identified. We would therefore recommend that SNB
techniques should remove a minimum of 4 nodes.
For patients with a positive sentinel node, the finding of
additional positive nodes in the axillary sample strongly
indicated the likelihood of further positive nodes in the
axilla, therefore, justifying an axillary clearance. If the SNB
was positive and the ANS negative, the likelihood of fur-
ther malignant nodes being revealed by an axillary clear-
ance was much lower (1/12, 8%) but with only this
limited evidence we still feel that this figure justifies pro-
ceeding to ANC.
Many parameters are correlated with the likelihood of
axillary node involvement [7,17,18]. We have examined
subgroups of our patients to try and determine whether
there is a group of patients whose pre-operative parame-
ters mean that even limited axillary surgery might be
safely avoided. Our previously reported experience of pal-
pable tumours has shown how difficult it is to predict the
histological size of invasive cancers [19]. This study has
demonstrated that even when clinical, ultrasound and
mammographic measurements indicate a tumour size of
15 mm or less, this was incorrect in 25 of 142 (18%) of
patients. It has been reported that pre-operative grade is
not reliably assessed without numerous core biopsies
which may be difficult on small cancers [20-22]. Lym-
phovascular invasion can only be evaluated on resected
Table 1: Axillary node status according to size and grade of tumour and presence of lymphovascular invasion
Grade LVI Number of positive nodes/ total nodes (%)
Tumour < 11 mm Tumour 15 – 11 
mm
Tumour >15 mm All tumours
1 LVI+ 0/3 (0%) 1/1 (100%) 0 1/4 (25%)
n = 55 LVI- 0/30 (0%) 2/15 (13%) 2/6 (33%) 4/51 (8%)
2L V I + 1/2 (50%) 1/3 (33%) 4/4 (100%) 6/9 (67%)
n = 67 LVI- 1/22 (5%) 1/27 (4%) 5/9 (56%) 7/58 (12%)
3L V I + 0 0/2 (0%) 1/2 (50%) 1/4 (25%)
n = 20 LVI- 2/7 (29%) 0/5 (0%) 1/4 (25%) 3/16 (19%)
G = grade (1–3)
LVI = Lymphovascular invasion (positive (+) or negative (-)International Seminars in Surgical Oncology 2005, 2:27 http://www.issoonline.com/content/2/1/27
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tumours [23]. Another pre-operative parameter that
might be accurately evaluated is oestrogen receptor status
on core biopsies [24-26]. However, our results demon-
strate that this alone was not useful.
An argument might be made to perform staged surgery
and look at the possible parameters on the formal histol-
ogy of the resected tumour. Tables 1 shows that in this
study, none of the parameters was able to reliably indicate
a group of patients with a low level (under 5%) of axillary
node involvement with the exception of grade 1 tumours
less than or equal to 15 mm or grade 2 tumours under 11
mm, both without lymphovascular invasion.
We also considered whether there could be a subgroup of
patients with small tumours whose pre-operative parame-
ters mean limited axillary surgery is inappropriate and
patients should proceed directly to radical axillary surgery.
However, revisiting Table 1 indicates that even patients
with the most unfavourable histology have at least a 50%
chance of being node negative supporting the concept of
initial limited axillary surgery.
In this study, additional axillary node sampling identified
13.6% (3/22) more node positive patients. Similarly, the
identification of positive sampled nodes in addition to a
positive sentinel node strongly predicted for further axil-
lary node involvement.
In summary, we propose the simple expedient of sam-
pling four nodes to increase the accuracy of sentinel node
biopsy.
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